Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	681.75	674.98	666.82	541.53	429.65	421.03
Revenue Growth (YoY)	1.88%	1.22%	23.14%	26.04%	2.05%	24.83%
Cost of Revenue	183.07	184.67	199.3	140.26	117.33	106.71
Gross Profit	498.69	490.31	467.53	401.28	312.32	314.31
Selling, General & Admin	270.62	269.44	254.52	199.35	193.52	200.78
Research & Development	77.36	76.26	84.8	55.55	59.42	72.12
Other Operating Expenses	46.73	56.94	68.19	56.46	13.03	30.93
Operating Expenses	394.71	402.63	407.5	311.35	265.97	303.83
Operating Income	103.98	87.68	60.02	89.92	46.35	10.48
Interest Expense / Income	14.03	20.31	39.98	31.75	25.67	23.63
Other Expense / Income	-11.87	5.67	6.75	1.77	0.59	-2.4
Pretax Income	101.82	61.7	13.3	56.4	20.09	-10.75
Income Tax	31.35	19.75	-2.61	14.42	-125.43	0.27
Net Income	70.47	41.96	15.91	41.98	145.52	-11.02
Net Income Growth	-	163.72%	-62.10%	-71.15%	-	-
Shares Outstanding (Basic)	46	46	46	44	43	42
Shares Outstanding (Diluted)	52	52	47	46	44	42
Shares Change	13.59%	11.69%	1.99%	4.46%	5.22%	1.47%
EPS (Basic)	1.52	0.91	0.35	0.95	3.41	-0.27
EPS (Diluted)	1.45	0.89	0.34	0.92	3.33	-0.27
EPS Growth	-	161.76%	-63.04%	-72.37%	-	-
Free Cash Flow	173.19	139.49	115.2	79.85	39.23	60.36
Free Cash Flow Per Share	3.73	3.02	2.53	1.80	0.92	1.45
Gross Margin	73.15%	72.64%	70.11%	74.10%	72.69%	74.65%
Operating Margin	15.25%	12.99%	9.00%	16.61%	10.79%	2.49%
Profit Margin	10.34%	6.22%	2.39%	7.75%	33.87%	-2.62%
Free Cash Flow Margin	25.40%	20.67%	17.28%	14.75%	9.13%	14.34%
Effective Tax Rate	30.79%	32.00%	-19.60%	25.57%	-624.39%	-
EBITDA	190.25	157.58	144.78	116.7	65.67	32.46
EBITDA Margin	27.91%	23.35%	21.71%	21.55%	15.28%	7.71%
Depreciation & Amortization	74.4	75.57	91.5	28.55	19.91	19.58
EBIT	115.85	82.01	53.28	88.15	45.76	12.88
EBIT Margin	16.99%	12.15%	7.99%	16.28%	10.65%	3.06%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).